Nolla Health, a healthtech startup originally from Norway, is making its debut in the U.S. market with a $4.5 million seed funding round led by General Catalyst. The company, which has already treated over 50,000 patients in Europe and ranks among the top medical apps in Norway, is establishing its U.S. headquarters in New York City. It is also rolling out its Acne Care app in more than 40 states.
Nolla Health aims to offer a comprehensive alternative to the fragmented digital health landscape by providing end-to-end dermatology care. For a monthly subscription fee of $59, users receive daily AI-powered skin assessments, personalized treatment plans reviewed by clinicians, and topical medications delivered directly to their homes.
Luis Wenus, co-founder and CEO, emphasizes the importance of personalized care that is consistently accessible and informed by the patient’s medical history. The company’s technology, trained on over one million dermatology cases and 1,600 conditions, allows for rapid diagnosis and prescription services, addressing the average 36-day wait time to see a dermatologist in the U.S. In Norway, the system has also identified numerous suspicious lesions for further examination.
Alongside General Catalyst, the funding round saw contributions from SNO Ventures and Commure’s founder, Diede van Lamoen. Nolla plans to use the investment to bolster its U.S. operations, hire additional clinical and engineering personnel, and develop new apps for other medical conditions. The launch of the Acne Care app marks the first step in Nolla’s mission to create AI-driven personal care companions.
